SBI-102 [SIRP-EV] Membrane Protein | ||
Discovery | IND-enabling | Clinical |
Severe Alcoholic Hepatitis | ||
Rare | ||
Efferocytosis of Inflammatory Dying Cells | ||
Acute on Chronic Liver Failure (ACLF) | ||
Rare | ||
Efferocytosis of Inflammatory Dying Cells /Phagocytosis of Pathological Fibroblasts | ||
Idiopathic Pulmonary Fibrosis (IPF) | ||
Rare | ||
Phagocytosis of Pathological Fibroblasts | ||
Pulmonary Arterial Hypertension (PAH) | ||
Rare | ||
Phagocytosis of Pathological Fibroblasts | ||
Nonalcoholic Steatohepatitis (NASH) | ||
Refractory | ||
Phagocytosis of Pathological Fibroblasts | ||
MSS Colorectal Cancer | ||
Refractory | ||
Phagocytosis of Cancer Cells | ||
SBI-201 [HIF1α-EV] Transcription Factor | ||
Discovery | IND-enabling | Clinical |
Peripheral Arterial Disease (PAD) | ||
Undisclosed | ||
| Resolutive Immunity Activation | ||
SBI-301 ASO | ||
Discovery | IND-enabling | Clinical |
Undisclosed | ||
Undisclosed | ||
| Undisclosed | ||
SBI-302 siRNA | ||
Discovery | IND-enabling | Clinical |
Undisclosed | ||
Undisclosed | ||
| Undisclosed | ||
aim to treat rare and refractory diseases with high unmet medical needs.
Program | Modality | Indication | Type | Mode of Action | Discovery | IND-enabling | Clinical |
SBI-102 [SIRP-EV] | Membrane Protein | Severe Alcoholic Hepatitis | Rare | Efferocytosis of Inflammatory Dying Cells | |||
Acute on Chronic | Rare | Efferocytosis of Inflammatory Dying Cells /Phagocytosis of Pathological Fibroblasts | |||||
Idiopathic Pulmonary | Rare | Phagocytosis of Pathological Fibroblasts | |||||
Pulmonary Arterial | Rare | Phagocytosis of Pathological Fibroblasts | |||||
Nonalcoholic Steatohepatitis | Refractory | Phagocytosis of Pathological Fibroblasts | |||||
MSS Colorectal Cancer | Refractory | Phagocytosis of Cancer Cells | |||||
SBI-201 [HIF1α-EV] | Transcription Factor | Peripheral Arterial | Undisclosed | Resolutive Immunity Activation | |||
SBI-301 | ASO | Undisclosed | Undisclosed | Undisclosed | |||
SBI-302 | siRNA | Undisclosed | Undisclosed | Undisclosed | |||
